Clinical Trials Logo

Clinical Trial Summary

It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain high relative dose intensity of anticancer treatments. Food supplement ONCOXIN (ONCX) contains amino acids, vitamins, minerals and biologically active substances of natural origin with high immunostimulatory and antioxidant activity. Present study is a real world experience study intended to evaluate the efficacy of ONCX in cancer patients.


Clinical Trial Description

The study was conducted at 9 centers across the Russia and Kazakhstan. Patients were allocated in 2:1 comparison groups for the ONCX and control groups, respectively. A total of 133 patients were enrolled in the study; 84 in the ONCX group and 49 as controls.

ONCX contains microelements, vitamins, amino acids and certain naturally occurring, biologically active substances.

It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain the Quality of life in cancer patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03550482
Study type Interventional
Source Catalysis SL
Contact
Status Completed
Phase Phase 4
Start date November 1, 2017
Completion date May 15, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05557552 - Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer N/A
Active, not recruiting NCT04765709 - Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC Phase 2
Not yet recruiting NCT06031597 - Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy Phase 3
Recruiting NCT04728724 - Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Phase 1/Phase 2
Completed NCT06015815 - The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
Completed NCT03728556 - A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer Phase 3
Recruiting NCT04586465 - Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC Phase 2
Not yet recruiting NCT05548504 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Phase 2
Completed NCT02434081 - NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma Phase 2
Not yet recruiting NCT02946216 - ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC N/A
Recruiting NCT05398094 - Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy Phase 2
Completed NCT02418234 - T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure N/A
Recruiting NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Phase 2
Not yet recruiting NCT05414630 - A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer Phase 2
Withdrawn NCT04941365 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy N/A
Active, not recruiting NCT04699721 - Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC Phase 1
Recruiting NCT04878952 - Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer N/A
Recruiting NCT04716946 - Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Phase 2
Completed NCT02623257 - EGFR Mutations on ctDNA in Patients With Advanced NSCLC N/A